Srdan Verstovsek, MD, PhD, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, chief of the Section of Myeloproliferative Neoplasms, MD Anderson Cancer Center, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.
Verstovsek says the JAK2 inhibitor improves quality of life in patients and was approved based on data from a recent phase III trial. He adds that the JAK2 inhibitor is important for myelofibrosis because it is the only approved treatment currently available.
Verstovsek says upcoming JAK2 inhibitors, such as momelotinib and pacritinib, may be able to improve quality of life for patients as well. Both momelotinib and pacritinib are currently undergoing trials.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More